Q-omics provides the consensus-scored NIFKP8 profile across patient tissues and cancer cell-line models. NIFKP8 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NIFKP8 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, NIFKP8 RNA expression shows 6,300 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LUAD, and TGCT as cancer lineages where NIFKP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIFKP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIFKP8 survival associations across molecular data types. NIFKP8 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIFKP8 RNA expression–survival associations across cancer types. High NIFKP8 expression shows unfavorable associations in KIRP, KIRC, LIHC, READ, UCS and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for NIFKP8 RNA expression.
This table summarizes NIFKP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NIFKP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIFKP8 shows lower tumor expression in LUAD and LUSC and higher tumor expression in BRCA. The LUAD box plot shows higher NIFKP8 RNA expression in normal versus tumor tissue (log2 FC = −0.265, t-test p < 0.001).
This table shows molecular features associated with NIFKP8 in patient tissues and cancer cell lines. In patient samples, NIFKP8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
